The aggravation of the aging of the Chinese population provides an important driving force for the development of the big health industry, coupled with the policy support, the improvement of the industry's research and development capabilities and other favorable factors, the development of the big health industry is thriving, becoming a sunrise industry that all parties are chasing and actively layouting, and relevant institutions predict that the scale of China's big health industry will reach 14.48 trillion yuan in 2023. At the same time, the development of the big health industry has a long way to go, how to accelerate the application of smart medical device innovation achievements? How to meet the explosive growth in telemedicine demand? How will household medical devices evolve? How wearable sensor technology can be applied to consumer-grade medical needs... A series of questions torture us, where is the innovation path of Chinese pharmaceutical companies?
| by Shanghai Poster Industry Group The 2021 [Interface Health Forum] hosted by Interface News will be held online on November 16. The forum will invite experts and leaders from various fields in the domestic academic community and industry to gather the strongest lineup to conduct in-depth exchanges in the form of keynote speeches and roundtable dialogues around innovative drugs, private medical treatment, Internet medical platforms, medical devices, consumer-grade medical treatment, health care products and other topics in the pharmaceutical industry, to explore a positive development path for China's pharmaceutical and health industry, and to look forward to a beautiful chapter in the future of "health". At the same time, the 2021 [Ivy Awards] final list and the 2021 pharmaceutical and health industry [super CEO] final list will also be announced at the ceremony, so stay tuned!
The forum set up two roundtable dialogues, one of which focused on the theme of "Innovation of Chinese Pharmaceutical Enterprises Going to sea", and the guests currently confirmed to attend the roundtable were: Dr. Wang Lai, Senior Vice President of BeiGene and Head of Global R&D, Dr. Zhang Lianshan, Senior Deputy General Manager & President of Global R&D of Jiangsu Hengrui Pharmaceutical Co., Ltd., Dr. Li Ning, CEO of Junshi Biotech, dr. Xu Jiaxi, Managing Director of Industrial Securities, Vice President of research institute and chief analyst of the pharmaceutical industry.
Dr. Wang Lai has been deeply involved in the pharmaceutical industry for nearly 30 years: more than 10 years of experience in biotechnology and more than 20 years of experience in cancer research. He worked as the R&D director of Joyant Pharmaceuticals, studied under Academician Wang Xiaodong, completed postdoctoral research at the Howard Hughes Medical Institute, and obtained a ph.D. from the University of Texas San Antonio Health Medical Center and a bachelor's degree from Fudan University.
Dr. Zhang Lianshan has held important positions in internationally renowned pharmaceutical companies such as Eli Lilly and Marcadia Biotech in the United States, and since 1988, he has been engaged in peptide methodology and new drug research and development for more than 30 years, and is highly accomplished in diabetes treatment drugs. After joining Hengrui Pharmaceutical, he led the team to develop a series of innovative drugs with international competitiveness, and the R&D pipeline comprehensively covered international hot targets and disease areas with major unmet clinical needs.
Dr. Ning Li is currently the Chief Executive Officer of Junshi Biologics, and prior to joining Junshi, he served as Vice President of Sanofi Group and Head of Pharmaceutical Policy and Medical Policy in Asia, with extensive experience in clinical research and drug science review. He also serves on the National Institutes of Health (NIH) Pharmaceutical Research Fund Review Committee, the National Institutes of Health Research Fund Review Special Committee, and the Johns Hopkins University Graduate Degree Program in Pharmacy Politics.
Dr. Xu Jiaxi is currently the managing director of Industrial Securities, and has won the first place in the pharmaceutical and biological industry of The Best Analyst of New Fortune for 6 times, the most popular analyst of insurance institutions for five consecutive times, the most influential analyst of the Golden Bull Award, and the Best Analyst award of Crystal Ball, Starmine and Forbes for many times. It has in-depth coverage of many fields of medicine and health, and the industry resources are abundant.
This forum will have 10 platforms to simultaneously broadcast the live event, and the audience can participate in the live wonderful content through the live broadcast channel.
For more details, please visit the 2021 [Interface Health Forum] topic
For selection and participation inquiries, please contact the Organizing Committee of the Forum:
Conference Team:
Ms. Yu 15821331789,[email protected]
Ms. Liu 18611097176,[email protected]
Media Groups:
Ms. Qian 18017751658,[email protected]